Repligen to Report First Quarter 2024 Financial Results
April 17, 2024 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2024 financial results on Wednesday, May 1, 2024....
Repligen Appoints Maggie A. Pax to Board of Directors
March 19, 2024 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences industry executive Maggie A. Pax....
Repligen Reports Fourth Quarter and Full Year 2023 Financial Results
February 21, 2024 07:30 ET
|
Repligen Corporation
Reports fourth quarter revenue of $156 million and full year revenue of $639 million Continued strength in orders with fourth quarter book-to-bill ratio of 1.03 WALTHAM, Mass., Feb. 21, 2024 ...
Repligen to Report Fourth Quarter and Full Year 2023 Financial Results
February 07, 2024 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter 2023 financial results on Wednesday, February 21,...
Repligen Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
December 19, 2023 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at...
Repligen Announces Private Convertible Transaction of $600 Million Principal Amount of 1.00% Convertible Senior Notes Due 2028 Through Exchange and New Subscription Agreements
December 07, 2023 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced that on December 6, 2023, it entered into privately negotiated exchange and/or subscription...
UPDATE – Repligen Announces Publication of the Company’s 2022 Sustainability Report
November 14, 2023 14:01 ET
|
Repligen Corporation
WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication...
Repligen Corporation to Present at Upcoming Investor Conferences
November 07, 2023 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be...
Repligen Launches TangenX® SC as First-to-Market Holder-Free Self-Contained TFF Device
November 02, 2023 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of...
Repligen Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance
October 31, 2023 07:30 ET
|
Repligen Corporation
Reports total third quarter revenues of $141.2 million, with base business revenues of $140.1 millionOrders strengthened with total book-to-bill ratio of 1.07 Narrows full year revenue guidance to...